NanoLogix Inc., an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”
The NanoLogix N-Assay (V) ELISA is one of six technologies that may be used for virus detection and identification, the N-Assay (V) has unique qualities that contribute to both its rapid detection capability and long term durability that should be attractive to personnel in both developed and remote locations interested in a screening test that may provide results for Ebola or other viral threats in 30 minutes to a few hours.
Sebastian Faro, MD, PhD, is considered one of the top experts in the world on Infectious diseases of women's reproductive systems. Dr. Faro made the following comments: "N-Assay ELISA technology has been applied to the rapid identification of specific bacteria, e.g. Streptococcus agalactiae (GBS), Neisseria gonorrhoeae, & Enterococcus faecalis. This technology has been used to rapidly identify strains that are resistant to specific antibiotics. This technology significantly reduces the time from specimen submission to identifying these bacteria and resistance to specific antibiotics. This N-Assay ELISA technology can be applied to identifying viruses and is inexpensive. This technology does not require expensive equipment which makes this technology ideal for a variety of laboratory environments.”
The NanoLogix N-Assay (V) ELISA is one of six technologies that may be used for virus detection and identification, the N-Assay (V) has unique qualities that contribute to both its rapid detection capability and long term durability that should be attractive to personnel in both developed and remote locations interested in a screening test that may provide results for Ebola or other viral threats in 30 minutes to a few hours.
Sebastian Faro, MD, PhD, is considered one of the top experts in the world on Infectious diseases of women's reproductive systems. Dr. Faro made the following comments: "N-Assay ELISA technology has been applied to the rapid identification of specific bacteria, e.g. Streptococcus agalactiae (GBS), Neisseria gonorrhoeae, & Enterococcus faecalis. This technology has been used to rapidly identify strains that are resistant to specific antibiotics. This technology significantly reduces the time from specimen submission to identifying these bacteria and resistance to specific antibiotics. This N-Assay ELISA technology can be applied to identifying viruses and is inexpensive. This technology does not require expensive equipment which makes this technology ideal for a variety of laboratory environments.”
Do you have more information about that? Thank you
ReplyDeleteThey are configuring their existing ELISA detection platform for Ebola. Therefore, I expect they are going to use Ebola antibodies on their proprietary substrate to capture the live virus and subsequently provide a fluorescent positive response. More info on their technology can be found on their website.
ReplyDelete